<DOC>
	<DOCNO>NCT02067299</DOCNO>
	<brief_summary>The purpose study evaluate effect JNJ-42847922 sleep latency ( latency persistent sleep ) participant major depressive disorder stably treat selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor suffer insomnia ( inability fall asleep ) .</brief_summary>
	<brief_title>A Study Investigate Effect JNJ-42847922 Polysomnography Measures Patients With Major Depressive Disorder With Insomnia Who Are Stably Treated With Antidepressants</brief_title>
	<detailed_description>This double-blind ( neither physician participant know treatment participant receives ) , placebo-controlled ( placebo compare study medication test whether study medication real effect clinical study ) , randomize ( study medication assign chance ) 4-way crossover ( method use switch participant 4 different arm clinical study ) , single dose study . This study consist screen phase ( 28 2 day prior study medication ) , treatment phase 4 double blind study period ( 2 day ) , follow-up phase ( within 7 14 day last dose study medication ) . Approximately 20 participant major depressive disorder participate study . Participants randomly assign 1 4 cohort ( group ) ( Cohorts A , B , C , D ) receive JNJ-42847922 ( 10 mg , 20 mg , 40 mg ) placebo . Each cohort consist 4 treatment period ( Periods 1 , 2 , 3 , 4 ) . Safety evaluate assessment vital sign , 12-lead electrocardiogram , clinical laboratory testing , physical examination , neurological examination . The total duration study participation participant approximately 9 10 week .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>Participants current/recurrent past episode Major Depressive Disorder ( MDD ) establish per mini international neuropsychiatric interview screen otherwise specify treat physician Stably treat selective serotonin reuptake inhibitor / serotoninnorepinephrine reuptake inhibitor monotherapy , change dose last 30 day screen Insomnia per polysomnography ( diagnostic test measure record physiologic variable like latency persistent sleep , total sleep time , sleep efficiency , time spent awake , total time spend deep sleep , sleep ) Participants must healthy / medically stable basis clinical laboratory test perform screen Female participant child bear potential due either tubal ligation hysterectomy postmenopausal ( spontaneous menses least 2 year ) Has current diagnosis psychotic disorder , MDD psychosis , bipolar disorder , mental retardation , cluster B personality disorder ( eg , borderline personality disorder , antisocial personality disorder ) Has diagnose sleeprelated breathe disorder Has suicidal ideation intent act , homicidal ideation/intent , per Principal Investigator 's clinical judgment Abnormal day/night rhythm , eg , nightshift worker , normal bed time past midnight Has uncontrolled hypertension screen Day 1 prior randomization ; past history hypertensive crisis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Depressive Disorder , Major</keyword>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Insomnia</keyword>
	<keyword>JNJ-42847922</keyword>
	<keyword>Placebo</keyword>
</DOC>